The future of ibrexafungerp for prevention of recurrent yeast infections

Video

Nkechi Azie, MD, MBA, FIDSA, vice president of clinical development and medical affairs at SCYNEXIS, discusses the potential FDA approval of ibrexafungerp (Brexafemme; SCYNEXIS) for the prevention of recurrent vulvovaginal candidiasis.

Note: BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp. Most common adverse reactions observed in clinical trials (incidence ≥2%) were diarrhea, nausea, abdominal pain, dizziness, and vomiting.
Related Videos
The importance of nipocalimab’s FTD against FNAIT | Image Credit:  linkedin.com
Revolutionizing menopause management: A deep dive into fezolinetant | Image Credit: uvahealth.com.
Approaching inflammatory vulvovaginal diseases | Image Credit: profiles.ucsf.edu.
How fezolinetant changes management of hot flashes | Image Credit: medschool.cuanschutz.edu.
Jermaine Gray
Marco Taglietti
Related Content
© 2024 MJH Life Sciences

All rights reserved.